Form 4: Akero COO Disposes Shares in Novo Nordisk Merger

Akero Therapeutics' Chief Operating Officer, Jonathan Young, disposed of all his direct and indirect holdings, including common stock, RSUs, and stock options, following the company's acquisition by Novo Nordisk A/S for $54.00 cash plus a $6.00 CVR.

Summary

• Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), reported the disposition of his beneficial ownership in the company.
• The dispositions occurred on December 9, 2025, as a result of the merger of Akero Therapeutics with NN Invest Sub, Inc., a subsidiary of Novo Nordisk A/S.
• Akero Therapeutics, Inc. survived the merger as a wholly-owned subsidiary of Novo Nordisk A/S.
• Each share of Akero common stock was cancelled and converted into the right to receive $54.00 in cash (Closing Consideration) and one contractual contingent value right (CVR) representing the right to receive an additional $6.00 in cash if a specified milestone is achieved.
• Young disposed of 152,616 shares of common stock held directly.
• He also disposed of 60,000 shares of common stock held indirectly through three irrevocable trusts (20,000 shares each for EA, CM, and JL Irrevocable Trusts).
• 47,573 restricted stock units (RSUs) held by Young were deemed fully vested and converted into the right to receive the Merger Consideration.
• A total of 512,082 stock options with various exercise prices ($19.87, $21.1, $28.35, $29.23, $42.95) were deemed fully vested, cancelled, and converted into a cash payment equal to the excess of the Closing Consideration over the option's exercise price, plus one CVR per share underlying the option.

Sentiment

Score: 7

Explanation: The filing reports the completion of an acquisition at a premium, which is generally positive for shareholders, but marks the end of the company's independent public trading. The CVR adds a layer of potential future value.

Positives

• The merger provides a clear exit strategy for shareholders, offering a fixed cash payment of $54.00 per share.
• The inclusion of a Contingent Value Right (CVR) for an additional $6.00 per share offers potential upside if a specified milestone is achieved, providing shareholders with a potential total of $60.00 per share.
• The transaction represents a successful acquisition for Akero Therapeutics, indicating value creation for its equity holders.

Negatives

• Akero Therapeutics, Inc. is no longer an independent publicly traded company, becoming a wholly-owned subsidiary of Novo Nordisk A/S.
• The reporting person, Jonathan Young, is no longer subject to Section 16 obligations for Akero Therapeutics, indicating a loss of direct public market oversight for his holdings in the company.

Risks

• The $6.00 per share contingent value right (CVR) is dependent on the achievement of a specified milestone, meaning the full $60.00 per share consideration is not guaranteed.

Future Outlook

Akero Therapeutics, Inc. is now a wholly-owned subsidiary of Novo Nordisk A/S, indicating its future operations and strategic direction will be integrated within Novo Nordisk's broader corporate structure.

Management Comments

• The dispositions were made pursuant to the terms of the Agreement and Plan of Merger, dated as of October 9, 2025.

Industry Context

This acquisition by Novo Nordisk A/S highlights the ongoing trend of consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller, innovative firms to expand their pipelines and market presence. Such mergers often provide significant premiums to the acquired company's shareholders.

Management Changes

Corporate Governance

Related Party Transactions

• Jonathan Young disclaims beneficial ownership of shares held in irrevocable trusts for his children, where his spouse is the trustee, except to the extent of his pecuniary interest. These shares were disposed of as part of the merger.

Stakeholder Impact

• Shareholders received a cash payment of $54.00 per share and a contingent value right (CVR) for an additional $6.00 per share, representing a significant return on their investment.
• Employees holding equity (like the COO) had their stock options and restricted stock units converted into cash and CVRs, providing liquidity and value realization.

Key Dates

Keywords

Akero Therapeutics, AKRO, Novo Nordisk, Merger, Acquisition, Form 4, Insider Transaction, Jonathan Young, Chief Operating Officer, Stock Options, Restricted Stock Units, CVR, Contingent Value Right